Drug Profile
Ranibizumab biosimilar - Primrose Bio
Alternative Names: PF-582Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Pfenex
- Developer Primrose Bio
- Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diabetic macular oedema; Retinal oedema; Wet age-related macular degeneration
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 01 Oct 2020 Pfenex has been acquired by Ligand Pharmaceuticals
- 07 Jun 2019 Ranibizumab biosimilar - Pfenex is available for licensing as of 01 Nov 2017. https://www.pfenex.com/